Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Development of Delayed Release Oral Formulation Comprising Esomeprazole Spray Dried Dispersion Utilizing Design of Experiment As An Optimization Strategy
AAPS PharmSciTech. 2023 Sep 12;24(7):186. doi: 10.1208/s12249-023-02642-4.ABSTRACTSolid dispersion (SD) technology is one of the most widely preferred solubility enhancement methods, especially for Biopharmaceutics classification system class II and IV drugs. Since the last decade, its application for the dual purpose of solubility hike and modified release using novel carriers has been in demand for its added advantages. Spray drying is a commercially accepted technique with high aspects of scalability and product characteristics. The current study used spray-dried dispersion to design delayed release capsule for the prot...
Source: AAPS PharmSciTech - September 12, 2023 Category: Drugs & Pharmacology Authors: Kaushika Patel Jaymin Patel Shreeraj Shah Source Type: research
Development of Delayed Release Oral Formulation Comprising Esomeprazole Spray Dried Dispersion Utilizing Design of Experiment As An Optimization Strategy
AAPS PharmSciTech. 2023 Sep 12;24(7):186. doi: 10.1208/s12249-023-02642-4.ABSTRACTSolid dispersion (SD) technology is one of the most widely preferred solubility enhancement methods, especially for Biopharmaceutics classification system class II and IV drugs. Since the last decade, its application for the dual purpose of solubility hike and modified release using novel carriers has been in demand for its added advantages. Spray drying is a commercially accepted technique with high aspects of scalability and product characteristics. The current study used spray-dried dispersion to design delayed release capsule for the prot...
Source: AAPS PharmSciTech - September 12, 2023 Category: Drugs & Pharmacology Authors: Kaushika Patel Jaymin Patel Shreeraj Shah Source Type: research
Development of Delayed Release Oral Formulation Comprising Esomeprazole Spray Dried Dispersion Utilizing Design of Experiment As An Optimization Strategy
AAPS PharmSciTech. 2023 Sep 12;24(7):186. doi: 10.1208/s12249-023-02642-4.ABSTRACTSolid dispersion (SD) technology is one of the most widely preferred solubility enhancement methods, especially for Biopharmaceutics classification system class II and IV drugs. Since the last decade, its application for the dual purpose of solubility hike and modified release using novel carriers has been in demand for its added advantages. Spray drying is a commercially accepted technique with high aspects of scalability and product characteristics. The current study used spray-dried dispersion to design delayed release capsule for the prot...
Source: AAPS PharmSciTech - September 12, 2023 Category: Drugs & Pharmacology Authors: Kaushika Patel Jaymin Patel Shreeraj Shah Source Type: research
Development of Delayed Release Oral Formulation Comprising Esomeprazole Spray Dried Dispersion Utilizing Design of Experiment As An Optimization Strategy
AAPS PharmSciTech. 2023 Sep 12;24(7):186. doi: 10.1208/s12249-023-02642-4.ABSTRACTSolid dispersion (SD) technology is one of the most widely preferred solubility enhancement methods, especially for Biopharmaceutics classification system class II and IV drugs. Since the last decade, its application for the dual purpose of solubility hike and modified release using novel carriers has been in demand for its added advantages. Spray drying is a commercially accepted technique with high aspects of scalability and product characteristics. The current study used spray-dried dispersion to design delayed release capsule for the prot...
Source: AAPS PharmSciTech - September 12, 2023 Category: Drugs & Pharmacology Authors: Kaushika Patel Jaymin Patel Shreeraj Shah Source Type: research
Pharmacological treatment of gastro-oesophageal reflux in children
CONCLUSIONS: There is very low-certainty evidence about symptom improvements and changes in pH indices for infants. There are no summary data for endoscopic changes. Medications may or may not provide a benefit (based on very low-certainty evidence) for infants whose symptoms remain bothersome, despite nonmedical interventions or parental reassurance. If a medication is required, there is no clear evidence based on summary data for omeprazole, esomeprazole (in neonates), H₂antagonists, and alginates for symptom improvements (very low-certainty evidence). Further studies with longer follow-up are needed. In older children...
Source: Cochrane Database of Systematic Reviews - August 27, 2023 Category: General Medicine Authors: Mark P Tighe Edward Andrews Iona Liddicoat Nadeem A Afzal Andrew Hayen R Mark Beattie Source Type: research
Pharmacological treatment of gastro-oesophageal reflux in children
CONCLUSIONS: There is very low-certainty evidence about symptom improvements and changes in pH indices for infants. There are no summary data for endoscopic changes. Medications may or may not provide a benefit (based on very low-certainty evidence) for infants whose symptoms remain bothersome, despite nonmedical interventions or parental reassurance. If a medication is required, there is no clear evidence based on summary data for omeprazole, esomeprazole (in neonates), H₂antagonists, and alginates for symptom improvements (very low-certainty evidence). Further studies with longer follow-up are needed. In older children...
Source: Cochrane Database of Systematic Reviews - August 27, 2023 Category: General Medicine Authors: Mark P Tighe Edward Andrews Iona Liddicoat Nadeem A Afzal Andrew Hayen R Mark Beattie Source Type: research
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole: A case report
We report a case of voriconazole-induced visual abnormality based on drug interaction of voriconazole and esomeprazole, therapeutic drug monitoring, and optimal therapy. An 81-year-old male developed visual abnormality after the blood concentration of voriconazole was up to 6.47 mg/L induced by coadministration with esomeprazole. Voriconazole is a substrate of multiple CYP450 isoenzymes including CYP2C19 (the major route), CYP3A4, and CYP2C9. Esomeprazole, a proton pump inhibitor (PPI), is also converted to inactive metabolites through CYP3A4 and CYP2C19-mediated metabolism, and is also a CYP2C19 inhibitor. The coadministr...
Source: Clinical Pharmacology and Therapeutics - August 7, 2023 Category: Drugs & Pharmacology Authors: Zhouqian Jiang Jia Li Chengfei Zhao Jie Chen Source Type: research
Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole: A case report
We report a case of voriconazole-induced visual abnormality based on drug interaction of voriconazole and esomeprazole, therapeutic drug monitoring, and optimal therapy. An 81-year-old male developed visual abnormality after the blood concentration of voriconazole was up to 6.47 mg/L induced by coadministration with esomeprazole. Voriconazole is a substrate of multiple CYP450 isoenzymes including CYP2C19 (the major route), CYP3A4, and CYP2C9. Esomeprazole, a proton pump inhibitor (PPI), is also converted to inactive metabolites through CYP3A4 and CYP2C19-mediated metabolism, and is also a CYP2C19 inhibitor. The coadministr...
Source: International Journal of Clinical Pharmacology and Therapeutics - August 7, 2023 Category: Drugs & Pharmacology Authors: Zhouqian Jiang Jia Li Chengfei Zhao Jie Chen Source Type: research
